Methods of detecting diseases or conditions

A method for assessing the efficacy of a treatment for a disease or condition in a subject, or for monitoring the progression or regression of a disease or condition in a subject, or for identifying a compound capable of ameliorating or treating a disease or condition in a subject, comprising:

• a) determining a first profile of one or more markers of the disease or condition from a first sample comprising two or more different components selected from the group consisting of:
• a cell-free bodily fluid isolated from the subject before the treatment, or at a first time point, or before administering the compound to the subject, a population of phagocytic cells isolated from the subject before the treatment, or at a first time point, or before administering the compound to the subject, a population of phagocytic cells having a DNA content more than 2n (>2n phagocytic cells) isolated from the subject before the treatment, or at a first time point, or before administering the compound to the subject, a population of circulating vesicles isolated from the subject before the treatment, or at a first time point, or before administering the compound to the subject, and a population of circulating diseased cells isolated from the subject before the treatment, or at a first time point, or before administering the compound to the subject;
• determining a second profile of at least one of the one or more markers from a first control comprising a component selected from the group consisting of:
• a population of phagocytic cells having a DNA content of 2n (=2n phagocytic cells) isolated from the subject before the treatment, or at the first time point, or before administering the compound to the subject, a population of non-phagocytic cells isolated from the subject before the treatment, or at the first time point, or before administering the compound to the subject, and a population of control cells isolated from the subject, or at the first time point, or before administering the compound to the subject, wherein the control cells are substantially free of cells affected by the disease or condition, before the treatment, or at the first time point, or before administering the compound to the subject;
• identifying a difference between the first and second profiles;
• b) determining a third profile of one or more markers of the disease or condition from a second sample comprising two or more different components selected from the group consisting of:
• a cell-free bodily fluid isolated from the subject after the treatment, or at a second time point, or after administering the compound to the subject, a population of phagocytic cells isolated from the subject after the treatment, or at a second time point, or after administering the compound to the subject, a population of phagocytic cells having a DNA content more than 2n (>2n phagocytic cells) isolated from the subject after the treatment, or at a second time point, or after administering the compound to the subject, a population of circulating vesicles isolated from the subject after the treatment, or at a second time point, or after administering the compound to the subject, and a population of circulating diseased cells isolated from the subject after the treatment, or at a second time point, or after administering the compound to the subject;
• determining a fourth profile of at least one of the one or more markers from a second control comprising a component selected from the group consisting of:
• a population of phagocytic cells having a DNA content of 2n (=2n phagocytic cells) isolated from the subject after the treatment, or at the second time point, or after administering the compound to the subject, a population of non-phagocytic cells isolated from the subject after the treatment, or at the second time point, or after administering the compound to the subject, and a population of control cells isolated from the subject, wherein the control cells are substantially free of cells affected by the disease or condition, after the treatment, or at the second time point, or after administering the compound to the subject;
• identifying a difference between the third and fourth profiles;
• and
• c) identifying a difference between the difference identified in a) and the difference identified in b) wherein the identified difference in c) is indicative of the efficacy of the treatment for said disease or condition in the subject, or of the progression or regression of said disease or condition in the subject, or that the compound is capable of ameliorating or treating said disease or condition in the subject, respectively.

A method for assessing the efficacy of a treatment for a disease or condition in a subject, or for monitoring the progression or regression of a disease or condition in a subject, or for identifying a compound capable of ameliorating or treating a disease or condition in a subject, comprising:

• a) determining a first profile of one or more markers of the disease or condition from a first sample comprising two or more different components selected from the group consisting of:
• a cell-free bodily fluid isolated from the subject before the treatment, or at a first time point, or before administering the compound to the subject, a population of phagocytic cells isolated from the subject before the treatment, or at a first time point, or before administering the compound to the subject, a population of phagocytic cells having a DNA content more than 2n (>2n phagocytic cells) isolated from the subject before the treatment, or at a first time point, or before administering the compound to the subject, a population of circulating vesicles isolated from the subject before the treatment, or at a first time point, or before administering the compound to the subject, and a population of circulating diseased cells isolated from the subject before the treatment, or at a first time point, or before administering the compound to the subject;
• b) determining a second profile of one or more markers of the disease or condition from a second sample comprising two or more different components selected from the group consisting of:
• a cell-free bodily fluid isolated from the subject after the treatment, or at a second time point, or after administering the compound to the subject, a population of phagocytic cells isolated from the subject after the treatment, or at a second time point, or after administering the compound to the subject, a population of phagocytic cells having a DNA content more than 2n (>2n phagocytic cells) isolated from the subject after the treatment, or at a second time point, or after administering the compound to the subject, a population of circulating vesicles isolated from the subject after the treatment, or at a second time point, or after administering the compound to the subject, and a population of circulating diseased cells isolated from the subject, or at a second time point, or after administering the compound to the subject;
• and
• c) identifying a difference between the first profile and the second profile, wherein the identified difference is indicative of the efficacy of the treatment for said disease or condition in the subject, or of the progression or regression of said disease or condition in the subject, or that the compound is capable of ameliorating or treating said disease or condition in the subject, respectively.

A method for diagnosing or aiding in the diagnosis of a disease or condition in a subject, or for assessing the risk of developing a disease or condition in a subject, or for prognosing or aiding in the prognosis of a disease or condition in a subject, comprising:

• a) determining a first profile of one or more markers of the disease or condition from a sample comprising components selected from the group consisting of:
• an analyte isolated from a cell-free bodily fluid isolated from the subject, an analyte isolated from a population of phagocytic cells isolated from the subject, an analyte isolated from a population of phagocytic cells having a DNA content more than 2n (>2n phagocytic cells) isolated from the subject, an analyte isolated from a population of circulating vesicles isolated from the subject, and an analyte isolated from a population of circulating diseased cells isolated from the subject;
• b) determining a second profile of at least one of the one or more markers from a control comprising a component selected from the group consisting of:
• an analyte isolated from a population of phagocytic cells having a DNA content of 2n (=2n phagocytic cells) isolated from the subject, an analyte isolated from a population of non-phagocytic cells isolated from the subject, and an analyte isolated from a population of control cells isolated from the subject, wherein the control cells are substantially free of cells affected by the disease or condition;
• and
• c) identifying a difference between the first and second profiles, wherein the difference is indicative of the presence of said disease or condition in the subject, or the risk of developing said disease or condition in the subject, or the prognosis of said disease or condition in the subject, respectively.

A method for assessing the efficacy of a treatment for a disease or condition in a subject, or for monitoring the progression or regression of a disease or condition in a subject, or for identifying a compound capable of ameliorating or treating a disease or condition in a subject, comprising:

• a) determining a first profile of one or more markers of the disease or condition from a first sample comprising two or more different components selected from the group consisting of:
• an analyte isolated from a cell-free bodily fluid isolated from the subject before the treatment, an analyte isolated from a population of phagocytic cells isolated from the subject before the treatment, or at a first time point, or before administering the compound to the subject, an analyte isolated from a population of phagocytic cells having a DNA content more than 2n (>2n phagocytic cells) isolated from the subject before the treatment, or at a first time point, or before administering the compound to the subject, an analyte isolated from a population of circulating vesicles isolated from the subject before the treatment, or at a first time point, or before administering the compound to the subject, and an analyte isolated from a population of circulating diseased cells isolated from the subject before the treatment, or at a first time point, or before administering the compound to the subject;
• determining a second profile of at least one of the one or more markers from a first control comprising a component selected from the group consisting of:
• an analyte isolated from a population of phagocytic cells having a DNA content of 2n (=2n phagocytic cells) isolated from the subject before the treatment, or at the first time point, or before administering the compound to the subject, an analyte isolated from a population of non-phagocytic cells isolated from the subject before the treatment, or at the first time point, or before administering the compound to the subject, and an analyte isolated from a population of control cells isolated from the subject, wherein the control cells are substantially free of cells affected by the disease or condition, before the treatment, or at the first time point, or before administering the compound to the subject;
• identifying a difference between the first and second profiles;
• b) determining a third profile of one or more markers of the disease or condition from a second sample comprising two or more different components selected from the group consisting of:
• an analyte isolated from a cell-free bodily fluid isolated from the subject after the treatment, or at a second time point, or after administering the compound to the subject, an analyte isolated from a population of phagocytic cells isolated from the subject after the treatment, or at a second time point, or after administering the compound to the subject, an analyte isolated from a population of phagocytic cells having a DNA content more than 2n (>2n phagocytic cells) isolated from the subject after the treatment, or at a second time point, or after administering the compound to the subject, an analyte isolated from a population of circulating vesicles isolated from the subject after the treatment, or at a second time point, or after administering the compound to the subject, and an analyte isolated from a population of circulating diseased cells isolated from the subject after the treatment, or at a second time point, or after administering the compound to the subject;
• determining a fourth profile of at least one of the one or more markers from a second control comprising a component selected from the group consisting of:
• an analyte isolated from a population of phagocytic cells having a DNA content of 2n (=2n phagocytic cells) isolated from the subject after the treatment, or at the second time point, or after administering the compound to the subject, an analyte isolated from a population of non-phagocytic cells isolated from the subject after the treatment, or at the second time point, or after administering the compound to the subject, and an analyte isolated from a population of control cells isolated from the subject, wherein the control cells are substantially free of cells affected by the disease or condition, after the treatment, or at the second time point, or after administering the compound to the subject;
• identifying a difference between the third and fourth profiles;
• and
• c) identifying a difference between the difference identified in a) and the difference identified in b) wherein the identified difference in c) is indicative of the efficacy of the treatment for said disease or condition in the subject, or of the progression or regression of said disease or condition in the subject, or that the compound is capable of ameliorating or treating said disease or condition in the subject, respectively.

A method for assessing the efficacy of a treatment for a disease or condition in a subject, or for monitoring the progression or regression of a disease or condition in a subject, or for identifying a compound capable of ameliorating or treating a disease or condition in a subject, comprising:

• a) determining a first profile of one or more markers of the disease or condition from a first sample comprising two or more different components selected from the group consisting of:
• an analyte isolated from a cell-free bodily fluid isolated from the subject before the treatment, or at a first time point, or before administering the compound to the subject, a population of phagocytic cells isolated from the subject before the treatment, or at a first time point, or before administering the compound to the subject, an analyte isolated from a population of phagocytic cells having a DNA content more than 2n (>2n phagocytic cells) isolated from the subject before the treatment, or at a first time point, or before administering the compound to the subject, an analyte isolated from a population of circulating vesicles isolated from the subject before the treatment, or at a first time point, or before administering the compound to the subject, and an analyte isolated from a population of circulating diseased cells isolated from the subject before the treatment, or at a first time point, or before administering the compound to the subject;
• b) determining a second profile of one or more markers of the disease or condition from a second sample comprising two or more different components selected from the group consisting of:
• an analyte isolated from a cell-free bodily fluid isolated from the subject after the treatment, or at a second time point, or after administering the compound to the subject, an analyte isolated from a population of phagocytic cells isolated from the subject after the treatment, or at a second time point, or after administering the compound to the subject, an analyte isolated from a population of phagocytic cells having a DNA content more than 2n (>2n phagocytic cells) isolated from the subject after the treatment, or at a second time point, or after administering the compound to the subject, an analyte isolated from a population of circulating vesicles isolated from the subject after the treatment, or at a second time point, or after administering the compound to the subject, and an analyte isolated from a population of control cells isolated from the subject, wherein the control cells are substantially free of cells affected by the disease or condition, after the treatment, or at a second time point, or after administering the compound to the subject;
• and
• c) identifying a difference between the first profile and the second profile, wherein the identified difference is indicative of the efficacy of the treatment for said disease or condition in the subject, or of the progression or regression of said disease or condition in the subject, or that the compound is capable of ameliorating or treating said disease or condition in the subject, respectively.

A method for diagnosing or aiding in the diagnosis of a disease or condition in a subject, or for assessing the risk of developing a disease or condition in a subject, or for prognosing or aiding in the prognosis of a disease or condition in a subject, comprising:

• a) determining a first profile of one or more markers of the disease or condition from a sample comprising two or more different components selected from the group consisting of:
• a cell-free bodily fluid isolated from the subject, a population of phagocytic cells isolated from the subject, a population of phagocytic cells having a DNA content more than 2n (>2n phagocytic cells) isolated from the subject, a population of circulating vesicles isolated from the subject, and a population of circulating diseased cells isolated from the subject;
• and
• b) identifying a difference between the first profile and a second profile of at least one of the one or more markers from a repository of said markers of said disease or condition, wherein the difference is indicative of the presence of said disease or condition in the subject, or the risk of developing said disease or condition in the subject, or the prognosis of said disease or condition in the subject, respectively.

A method for diagnosing or aiding in the diagnosis of a disease or condition in a subject, or for assessing the risk of developing a disease or condition in a subject, or for prognosing or aiding in the prognosis of a disease or condition in a subject, comprising:

• a) determining a first profile of one or more markers of the disease or condition from a sample comprising components selected from the group consisting of:
• an analyte isolated from a cell-free bodily fluid isolated from the subject, an analyte isolated from a population of phagocytic cells isolated from the subject, an analyte isolated from a population of phagocytic cells having a DNA content more than 2n (>2n phagocytic cells) isolated from the subject, an analyte isolated from a population of circulating vesicles isolated from the subject, and an analyte isolated from a population of circulating diseased cells isolated from the subject;
• and
• b) identifying a difference between the first profile and a second profile of at least one of the one or more markers from a repository of said markers of said disease or condition, wherein the difference is indicative of the presence of said disease or condition in the subject, or the risk of developing said disease or condition in the subject, or the prognosis of said disease or condition in the subject, respectively.

A method for identifying one or more markers for a disease or condition comprising:

• a) determining a first profile of analytes from a sample comprising a cell-free bodily fluid from a subject having said disease or condition and a population of phagocytic cells, or a population of >2n phagocytic cells, from a subject having said disease or condition;
• determining a second profile of analytes from a population of =2n phagocytic cells, or a population of non-phagocytic cells, from the subject having said disease or condition;
• identifying a set of differences between the first and second profiles, wherein the first set of differences is specific to the first profile relative to the second profile;
• b) determining a third profile of analytes from a sample comprising a cell-free bodily fluid from a subject having said disease or condition and a population of phagocytic cells, or a population of >2n phagocytic cells, from a control subject not having said disease or condition;
• determining a fourth profile of analytes from a population of =2n phagocytic cells, or a population of non-phagocytic cells, from the control subject not having said disease or condition;
• identifying a set of differences between the third and fourth profiles, wherein the second set of differences is specific to the third profile relative to the fourth profile;
• and
• c) identifying one or more analytes specific to the set of differences identified in a) relative to the set of differences identified in b), the identified analytes in c) being markers of said disease or condition.

A method for identifying one or more markers for a disease or condition comprising:

• a) determining a first profile of analytes from a sample comprising a cell-free bodily fluid from a subject having said disease or condition and a population of phagocytic cells, or a population of >2n phagocytic cells, from a subject having said disease or condition;
• b) comparing the first profile to a second profile derived from a repository of analytes from a control subject not having said disease or condition;
• c) identifying a set of differences between the first and second profiles, wherein the set of differences is specific to the first profile relative to the second profile;
• and
• d) identifying one or more analytes specific to the set of differences, the identified analytes being markers of said disease or condition.